Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15518427 | 1.00 | HSD17B10 (0.39) | HSD17B10SLC6A9MGLLTSHRS1PR1 | |
| SCHEMBL17057486 | 0.95 | HSD17B10 (0.36) | HSD17B10SLC6A9MGLLTSHRS1PR1 | |
| SCHEMBL17053358 | 0.95 | HSD17B10 (0.36) | HSD17B10SLC6A9MGLLTSHRS1PR1 | |
| SCHEMBL12238070 | 0.92 | LMNA (0.36) | HSD17B10TSHRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL437100 | 0.92 | LMNA (0.36) | HSD17B10TSHRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL12038457 | 0.91 | CHRM5 (0.35) | HSD17B10SLC6A9TSHR | |
| SCHEMBL14522328 | 0.91 | CHRM5 (0.35) | HSD17B10SLC6A9TSHR | |
| SCHEMBL25039379 | 0.90 | HSD17B10 (0.33) | HSD17B10SLC6A9 | |
| SCHEMBL23662688 | 0.90 | SLC6A9 (0.33) | HSD17B10SLC6A9TSHR | |
| SCHEMBL12231841 | 0.90 | CHRM5 (0.34) | HSD17B10SLC6A9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1059 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | PETER MACCALLUM CANCER INST (AU) | 2026-03-19 | — | — | US | claimed |
| CN-119954902-A | PD-L1 targeted compound HF12, and preparation method and application thereof | 中山大学附属第一医院 | 2025-05-09 | — | — | CN | claimed |
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-24 | — | — | US | claimed |
| CN-119798325-A | Radiolabel, precursor compound thereof, preparation method and application | 西南医科大学附属医院 | 2025-04-11 | — | — | CN | claimed |
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | MERCK PATENT GMBH (DE) | 2025-04-03 | — | — | US | claimed |
| WO-2025040588-A1 | MONOCLONAL ANTI-PTK7 ANTIBODIES AND DERIVATIVES | ONCOINVENT AS (NO) | 2025-02-27 | — | — | WO | claimed |
| US-12194109-B2 | Radioactive compound for treatment of melanoma and use thereof | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2025-01-14 | — | — | US | claimed |
| US-20240415989-A1 | RADIOLABELED COMPOUND, AND PRECURSOR COMPOUND THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY (CN) | 2024-12-19 | — | — | US | claimed |
| EP-4472677-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | claimed |
| EP-4472676-A1 | THERAGNOSTIC FOLATE CONJUGATES | Merck Patent GmbH (DE) | 2024-12-11 | — | — | EP | claimed |
| WO-2022232124-A1 | TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| CN-114230610-A | Radiolabel, precursor compound thereof, preparation method and application | 西南医科大学附属医院 | 2022-03-25 | — | — | CN | claimed |
| US-20220031873-A1 | Multi-Modal Contrast Agent For Medical Imaging | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-02-03 | — | — | US | claimed |
| US-10973925-B2 | Methods and compositions for theranostic nanoparticles | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION INC. (US) | 2021-04-13 | — | — | US | claimed |
| EP-3474879-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | University of Iowa Research Foundation (US) | 2019-05-01 | — | — | EP | claimed |
| US-10011587-B2 | Multivalent ligands targeting VEGFR | THE METHODIST HOSPITAL SYSTEM (US) | 2018-07-03 | — | — | US | claimed |
| WO-2017223565-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-12-28 | — | — | WO | claimed |
| WO-2017176216-A1 | A MULTIMODAL FLUORESCENT PROBE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-12 | — | — | WO | claimed |
| US-9603954-B2 | Methods for generating radioimmunoconjugates | ACTINIUM PHARMACEUTICALS INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20120220754-A1 | METHODS FOR GENERATING RADIOIMMUNOCONJUGATES | ACTINIUM PHARMACEUTICALS INC. (US) | 2012-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108138-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, MTHFD1, MTHFD2 | HSD17B10 1876/4885SLC6A9 1460/4885MGLL 3992/4885 |
| US-12194109-B2 | Radioactive compound for treatment of melanoma and use thereof | CD47, TYR, NRAS | HSD17B10 4685/4885SLC6A9 4810/4885MGLL 1905/4885 |
| US-20250127938-A1 | THERAGNOSTIC FOLATE CONJUGATES | FOLR1, FOLR2, DHFR | HSD17B10 3985/4885SLC6A9 1595/4885MGLL 4286/4885 |
| US-20240415989-A1 | RADIOLABELED COMPOUND, AND PRECURSOR COMPOUND THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | TMEM14C, FURIN, SLC7A1 | HSD17B10 4346/4885SLC6A9 609/4885MGLL 2002/4885 |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | CCKAR, NPY1R, NPY2R | HSD17B10 2752/4885SLC6A9 191/4885MGLL 660/4885 |
| US-10011587-B2 | Multivalent ligands targeting VEGFR | KDR, FLT4, FLT1 | HSD17B10 4837/4885SLC6A9 4607/4885MGLL 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.